General Gastro News Articles

Gastro

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Yu AP et al. – This analysis suggests that adalimumab maintenance therapy is a dominant strategy versus infliximab maintenance therapy for patients with moderate to severe Crohn's disease. Adalimumab appeared more effective and less costly than infliximab.

Related Articles

Impact of disease activity on resting energy expenditure in children with inflammatory bowel disease
Clinical Nutrition, 11/30/09    Relevance Score: 69%

A Case-Control Study on Risk Factors of Osteoporosis in Patients with Crohn's Disease
Archives of Iranian Medicine, 11/13/09    Relevance Score: 69%

Gastrointestinal stromal tumor causing small bowel intussusception in a patient with Crohn's disease
World Journal of Gastroenterology, 11/13/09    Relevance Score: 68%

Pathogenesis of inflammatory bowel disease (IBD)
The Internet Journal of Gastroenterology, 11/13/09    Relevance Score: 68%

Methotrexate for maintenance of remission in Crohn's disease
Cochrane Reviews, 10/27/09    Relevance Score: 68%

Today in Pharmacology/kinetics...keeping you current

Multidrug resistance protein 3 R652G may reduce susceptibility to idiopathic infant cholestasis
World Journal of Gastroenterology, 12/16/09

Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium After Simultaneous Pancreas-Kidney Transplantation
Transplantation Proceedings, 12/16/09

Efficacy and Safety of Lubiprostone in Patients with Chronic Constipation
Digestive Diseases and Sciences, 12/16/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address